Venture capitalists put more cash into more deals for medical device companies during the 3rd quarter, according to a report from PricewaterhouseCoopers.
Medical device companies pulled down $586 million in 78 deals during the 3rd quarter, up 13% in dollars and 18% in deal volume compared with Q3 2013.
Venture capitalists put more skin in fewer deals during the 1st quarter, amid an overall decline in life science deals, according to a survey of VC shops.
The number of deals for the medical device & equipment sector dropped 37% to 61 transactions, but the total value of those deals rose 28% to $588 million, according to the MoneyTree report from PricewaterhouseCoopers LLP and the National Venture Capital Assn., based on data provided by Thomson Reuters.
Venture capital funding of life science startups, including biotech and medical device enterprises, rose by 21% last year, according to PricewaterhouseCoopers.
VCs dropped $7.5 billion on 785 life sciences deals during the year, according to a PwC report, "Zigzagging Upward," compiled using data from the PricewaterhouseCoopers LLP/National Venture Capital Assn. MoneyTree Report and Thomson Reuters.